Tizona Therapeutics, Inc.

13 articles with Tizona Therapeutics, Inc.

• 

  BioSpace Movers & Shakers, Sept. 18

  9/18/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Tizona Appoints Christine O’Brien as Chief Executive Officer

  9/15/2020

  Tizona Therapeutics, Inc., a clinical stage, privately held company developing first-in-class cancer immunotherapies, today announced the appointment of Christine O’Brien as Chief Executive Officer, effective immediately

• Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million

  7/21/2020

  Gilead to Acquire 49.9% Equity Interest in Tizona – – Gilead Will Have Right to Acquire Remainder of Tizona for up to $1.25 Billion in Potential Option Fees and Future Milestone Payments – – Gilead Research and Development Funding to Accelerate Tizona’s First-in-Class Pipeline –

• Tizona Initiates Clinical Development of TTX-080 in Advanced Cancers

  6/25/2020

  Tizona Therapeutics, Inc., a privately held, clinical stage company developing first-in-class cancer immunotherapies, announced that its Investigational New Drug application for TTX-080, a novel antibody targeting HLA-G, has been cleared by the U.S. Food and Drug Administration.

• Tizona to Present at The Cowen and Company 40th Annual Healthcare Conference

  2/19/2020

  Tizona Therapeutics, Inc., a clinical stage, privately held company developing first-in-class cancer immunotherapies, announced today that Scott Clarke, Chief Executive Officer, will present at The Cowen and Company 40th Annual Healthcare Conference on Wednesday, March 4th a

• Tizona Announces Publication in Cancer Discovery Highlighting the Important Role of CD39 and Extracellular ATP in Inflammasome-driven Anti-Tumor Immunity

  11/7/2019

  Tizona Therapeutics, Inc., a clinical stage, privately held company developing first-in-class cancer immunotherapies, announced today the online publication of an article in Cancer Discovery describing novel mechanisms to more potently modulate the adenosine pathway and activate anti-tumor immune responses using antibodies that block CD39.

• Tizona Appoints Joyson Karakunnel, MD, MSc, FACP as Senior Vice President and Chief Medical Officer

  7/11/2019

  Tizona Therapeutics, Inc., a clinical stage, privately held immunotherapy company, today announced the appointment of Joyson Karakunnel, MD, MSc, FACP as Senior Vice President and Chief Medical Officer .

• Tizona Elects Daniel K. Spiegelman to Its Board of Directors

  5/15/2019

  Tizona Therapeutics, Inc., a privately held immunotherapy company, today announced the appointment of Daniel K. Spiegelman to its Board of Directors. 

• Tizona Announces Initiation of Phase 1/1b Study with Novel Cancer Immunotherapy TTX-030 and First Public Presentation of Pre-Clinical Data with TTX-030 at AACR 2019

  3/27/2019

  TTX-030 is the first anti-CD39 therapeutic to be studied in patients

• 

  AbbVie Forges $105 Million+ CD39 Inhibitor Alliance With Tizona

  1/4/2019

  Privately-held Tizona Therapeutics snagged $105 million in upfront cash as its cancer antibody TTX-030 is the centerpiece of a collaborative effort with Illinois-based AbbVie.

• AbbVie and Tizona Therapeutics Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39

  1/3/2019

  Initiation of clinical studies with TTX-030 is targeted in Q1 2019

• Tizona Therapeutics Appoints George Golumbeski, Ph.D., To Its Board Of Directors

  8/30/2016

• Bay Area's Tizona Therapeutics Emerges from Stealth Mode with $70 Million Total in Financing

  3/9/2016